Risk Factors for Poor Visual Outcome and Myopia in Retinopathy of Prematurity
Abstract
Objective: To identify risk factors for poor visual outcomes and myopia in stage 1-3 retinopathy of prematurity (ROP).
Material and Methods: Data from 116 patients with ROP (209 eyes) at a tertiary hospital between January 2011 and December 2020 were analyzed. Participants were categorized into three groups: observed, laser, and combined laser with intravitreal bevacizumab. Final visual acuity (VA) and refractive error changes with age and risk factors for poor visual outcomes and myopia were analyzed.
Results: The mean age at the last follow-up was 5.42±2.12 years. Median final refractive error (spherical equivalent) was 0.81 D (0.25, 1.38), 0.13 D (-2.0, 1.0), and -9.63 D (-13.25, -1.94), and median final logMAR VA was 0.18 (0, 1.3), 0.3 (0.1, 0.9), and 0.5 (0.18, 1.12), in the observed, laser, and combined groups, respectively. Individuals with severe ROP tended to develop high myopia at an early age. Multivariate analyses revealed treatment before postmenstrual age of 35 weeks, laser spots >600, and strabismus as risk factors for myopia <-3 D at age 3. The odds for myopia increased 2.37 times for every 100 laser spots. Risk factors for VA <20/40 were male sex, ROP requiring laser treatment, and strabismus.
Conclusion: Early ROP treatment, increased laser spots, and strabismus increase the risk of developing myopia and impaired VA at a young age.
Keywords
Full Text:
PDFReferences
Fierson WM, American Academy of Pediatrics, Section on Ophthalmology, American Academy of Ophthalmology, et al. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2018;142:e20183061.
Good WV. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 2004;102:233-48.
Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-15.
Wiecek E, Akula JD, Vanderveen DK, Mantagos IS, Wu C, Curran AL, et al. Longitudinal change of refractive error in retinopathy of prematurity treated with intravitreal bevacizumab or laser photocoagulation. Am J Ophthalmol 2022;240:252-9.
Tan QQ, Christiansen SP, Wang J. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: a meta-analysis and systematic review. PLoS One 2019;14:e0225643.
Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev 2018;1:Cd009734.
Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 2012;130:1000-6.
Quinn GE, Dobson V, Davitt BV, Hardy RJ, Tung B, Pedroza C, et al. Progression of myopia and high myopia in the Early Treatment for Retinopathy of Prematurity study: findings at 4 to 6 years of age. J AAPOS 2013;17:124-8.
Thakur S, Kumari S, Sanghavi V, Belenje A, Bhate M, Ranjan Padhi T, et al. Myopia dominance in preterm infants without and with retinopathy of prematurity: Indian Twin Cities ROP study (ITCROPS) report number 15. Acta Ophthalmol 2024;103:e86-93.
Tachikawa T, Ueno R, Mita T, Yuzurihara D, Katsumi O, Noda T, et al. Refractive state and visual acuity of children with extremely low birth weight at 3 years old in Japan. Jpn J Ophthalmol 2020;64:539-48.
Simmons M, Wang J, Leffler JN, Li S, Morale SE, de la Cruz A, et al. Longitudinal development of refractive error in children treated with intravitreal bevacizumab or laser for retinopathy of prematurity. Transl Vis Sci Technol 2021;10:14.
Young-Zvandasara T, Popiela M, Preston H, Seow E, Watts P. Is the severity of refractive error dependent on the quantity and extent of retinal laser ablation for retinopathy of prematurity? Eye (Lond) 2020;34:740-5.
Inoue T, Asaoka R, Hashimoto Y, Kitamoto K, Kitano M, Fujita A, et al. Does the number of laser applications for ROP treatment influence the degree of myopia? Graefes Arch Clin Exp Ophthalmol 2021;259:317-22.
Hwang ES, Kassem IS, Allozi R, Kravets S, Al-Kirwi KY, Hallak JA, et al. Association between myopia progression and quantity of laser treatment for retinopathy of prematurity. PLoS One 2022;17:e0279898.
Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 2014;132:1327-33.
Asano S, Inoue T, Kure K, Kitano M, Fujita A, Nagahara M, et al. Investigating the factors affecting myopia in retinopathy of prematurity after laser treatment. Int J Retina Vitreous 2023;9:27.
Hellgren KM, Tornqvist K, Jakobsson PG, Lundgren P, Carlsson B, Källén K, et al. Ophthalmologic Outcome of Extremely Preterm Infants at 6.5 Years of Age: Extremely Preterm Infants in Sweden Study (EXPRESS). JAMA Ophthalmol 2016;134:555-62.
Nishi T, Ueda T, Mizusawa Y, Shinomiya K, Mitamura Y, Kimura N, et al. Effect of foveal morphology on visual acuity in 4-6-year-old children with retinopathy of prematurity: a J-CREST study. Sci Rep 2022;12:16431.
VanderVeen DK, Bremer DL, Fellows RR, Hardy RJ, Neely DE, Palmer EA, et al. Prevalence and course of strabismus through age 6 years in participants of the Early Treatment for Retinopathy of Prematurity randomized trial. J AAPOS 2011;15:536-40.
Larsson E, Hellström A, Tornqvist K, Wallin A, Sunnqvist B, Sandgren Hochhard K, et al. Ophthalmological outcome of 6.5 years children treated for retinopathy of prematurity: a Swedish register study. Br J Ophthalmol 2023;108:137-42.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.